Structural Basis for the Deactivation of the Estrogen-related Receptor γ by Diethylstilbestrol or 4-Hydroxytamoxifen and Determinants of Selectivity
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The estrogen-related receptor (ERR) gamma behaves as a constitutive activator of transcription. Although no natural ligand is known, ERRgamma is deactivated by the estrogen receptor (ER) agonist diethylstilbestrol and the selective ER modulator 4-hydroxytamoxifen but does not significantly respond to estradiol or raloxifene. Here we report the crystal structures of the ERRgamma ligand binding domain (LBD) complexed with diethylstilbestrol or 4-hydroxytamoxifen. Antagonist binding to ERRgamma results in a rotation of the side chain of Phe-435 that partially fills the cavity of the apoLBD. The new rotamer of Phe-435 displaces the "activation helix" (helix 12) from the agonist position observed in the absence of ligand. In contrast to the complexes of the ERalpha LBD with 4-hydroxytamoxifen or raloxifene, helix 12 of antagonist-bound ERRgamma does not occupy the coactivator groove but appears to be completely dissociated from the LBD body. Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha. Our results provide detailed molecular insight into the conformational changes occurring upon binding of synthetic antagonists to the constitutive orphan receptor ERRgamma and reveal structural differences with ERs that explain why ERRgamma does not bind estradiol or raloxifene and will help to design new selective antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355 · cited 7×
“In most documented cases AF2 antagonism is based on sterical interference between a bulky ligand extension protruding from the LBP and H12 in the agonist position, as exemplified by the ERα LBD bound to RAL or 4-OHT (28, 29) or the ERβ LBD complexed with ICI 164,384 (ICI) (30).”
BackgroundInfluentialA unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208
Kamei, Y., Ohizumi, H., Fujitani, Y., Nemoto, T., Tanaka, T., Takahashi, N., Kawada, T., Miyoshi, M., Ezaki, O., & Kakizuka, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135217100 · Cited by 357
Cited by
Overview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 499
Okada, H., Tokunaga, T., Liu, X., Takayanagi, S., Matsushima, A., & Shimohigashi, Y. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.10587 · Cited by 446
Takayanagi, S., Tokunaga, T., Liu, X., Okada, H., Matsushima, A., & Shimohigashi, Y. (2006) · Toxicology Letters · doi:10.1016/j.toxlet.2006.08.012 · Cited by 407
LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS
Nettles, K. W., & Greene, G. L. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 268
Virgili, F., & Marino, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.08.001 · Cited by 250
“This hypothesis has been validated through the discovery that the ER agonist diethylstilbestrol can act as an inverse agonist on all three ERR isoforms [172], whereas the SERM 4-hydroxytamoxifen acts as an isoform-specific ERR inverse agonist [173,174].”
Huss, J. M., Garbacz, W. G., & Xie, W. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.06.016 · Cited by 220
Keay, J., Bridgham, J. T., & Thornton, J. W. (2006) · Endocrinology · doi:10.1210/en.2006-0363 · Cited by 211
Bottegoni, G., Kufareva, I., Totrov, M., & Abagyan, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8009958 · Cited by 180
Estrogen-Related Receptors as Emerging Targets in Cancer and Metabolic Disorders
Ariazi, E., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026610606030203 · Cited by 168
Stabilization of protein-protein interactions in drug discovery
Andrei, S. A., Sijbesma, E., Hann, M., Davis, J., O’Mahony, G., Perry, M. W. D., Karawajczyk, A., Eickhoff, J., Brunsveld, L., Doveston, R. G., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1346608 · Cited by 163
“ERR γ is a constitutively active NR. Binding of 4HT induces a major conformational rearrangement of the ERR γ LBD resulting in the displacement of helix 12 and thus favoring the recruitment of co-repressors [137].”
Hirvonen, J., Rajalin, A.-M., Wohlfahrt, G., Adlercreutz, H., Wähälä, K., & Aarnisalo, P. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.001 · Cited by 35
Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors
Lu, X., Peng, L., Lv, M., & ding, K. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212801227113 · Cited by 28
“The new rotamer of phe435 led to a steric clash with Leu454 and phe450 in H12, and displaced H12 (AF-2) from its agonist position capping the LBP [53,54].”
Background
Metadata
- Authors
- Greschik, H., Flaig, R., Renaud, J.-P., & Moras, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 279
- Issue
- 32
- Pages
- 33639-33646
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2040638528
- Cited by
- 129
- References
- 3
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.